Diaceutics (LON:DXRX – Get Free Report) issued its earnings results on Tuesday. The company reported GBX (3.27) EPS for the quarter, Digital Look Earnings reports. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.
Diaceutics Price Performance
Diaceutics stock opened at GBX 191.50 on Thursday. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43. Diaceutics has a 52 week low of GBX 125 and a 52 week high of GBX 197. The stock has a market capitalization of £162.51 million, a P/E ratio of 1,740.91 and a beta of 0.88. The stock has a fifty day moving average of GBX 146.97 and a 200-day moving average of GBX 151.24.
Analyst Ratings Changes
Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 215.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Featured Stories
- Five stocks we like better than Diaceutics
- 3 Energy ETFs Built for Oil’s New $100-Plus Reality
- Can Marvell Keep Up in the Custom AI Chip Race?
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
